ArticleBioengineering (Basel, Switzerland)2025
From Anatomy to Genomics Using a Multi-Task Deep Learning Approach for Comprehensive Glioma Profiling.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Microscopic Pollen Image Classification via Contour-Signal Representation, Wavelet Analysis, and CNN.Journal of imaging · 2026Article
- Classification and Segmentation of Medical Images Using Cross-Representation Attention Fusion and Fuzzy Image Enhancement.Sensors (Basel, Switzerland) · 2026Article
- Integrated CT-PET radiogenomics and graph-based multi-task learning for preoperative prediction of key glioma molecular markers.Neuroradiology · 2026Article
- Multimodal artificial intelligence in glioma management: integrating neuroimaging and hematologic biomarkers for precision oncology.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGliomas are among the most complex and lethal primary brain tumors, necessitating precise evaluation of both anatomical subregions and molecular alterations for effective clinical management.
methodsTo find a solution to the disconnected nature of current bioimage analysis pipelines, where anatomical segmentation based on MRI and molecular biomarker prediction are done as separate tasks, we use here Molecular-Genomic and Multi-Task (MGMT-Net), a one deep learning scheme that carries out the task of the multi-modal MRI data without any conversion. MGMT-Net incorporates a novel Cross-Modality Attention Fusion (CMAF) module that dynamically integrates diverse imaging sequences and pairs them with a hybrid Transformer-Convolutional Neural Network (CNN) encoder to capture both global context and local anatomical detail. This architecture supports dual-task decoders, enabling concurrent voxel-wise tumor delineation and subject-level classification of key genomic markers, including the IDH gene mutation, the 1p/19q co-deletion, and the TERT gene promoter mutation.
resultsExtensive validation on the Brain Tumor Segmentation (BraTS 2024) dataset and the combined Cancer Genome Atlas/Erasmus Glioma Database (TCGA/EGD) datasets demonstrated high segmentation accuracy and robust biomarker classification performance, with strong generalizability across external institutional cohorts. Ablation studies further confirmed the importance of each architectural component in achieving overall robustness.
conclusionsMGMT-Net presents a scalable and clinically relevant solution that bridges radiological imaging and genomic insights, potentially reducing diagnostic latency and enhancing precision in neuro-oncology decision-making. By integrating spatial and genetic analysis within a single model, this work represents a significant step toward comprehensive, AI-driven glioma assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.